![137735-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137735-Thumbnail%20Image.png?versionId=p0eXeP2d03kcFVsH6Euhiot_ftbbE3Gt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=59292f0c61db9dd0f6fad453682f193d9c2d7b6018f4a2523a3f13fdd50cecc3&itok=v4vqSaHP)
![137273-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137273-Thumbnail%20Image.png?versionId=Hu0K4Z1UUNTw5dQPNolgpjvNAy5jiqLb&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240606/us-west-2/s3/aws4_request&X-Amz-Date=20240606T101147Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=cda817c6ebc99ba1eabf93a5773e0c75d207e873997ad0f63b544588498d75ea&itok=E-z8Q_a2)
![137413-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137413-Thumbnail%20Image.png?versionId=Wv27ioPs6mvEZNOX9ZI2JpfsM9Rw79oM&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T235936Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=a3efc46a79c9f52d040c6424b20949522e6050bc0b070f8d3e20893160dd5796&itok=6E7e336R)
![137471-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137471-Thumbnail%20Image.png?versionId=oBm7GR8SlMoe01GHGkxRpxffqdtTIygj&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=4559ab9e0e7893b04a4275e191362932a202d2e816494fdfe5d803f01d33e3d3&itok=8MaqFm5-)
![136571-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136571-Thumbnail%20Image.png?versionId=B_bmZ0K8fCXnwNcGlw_rvi7KyKtlyAbo&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T202724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5b3949d006bbdf5cf2c62b585b2759b527a29cd9e7b35db738f59734997844c5&itok=t-KZLV2M)
![141463-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-06/141463-Thumbnail%20Image.png?versionId=ENeUABe2Oyxa57Ihl_PyS6yF4grzWvE3&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T154456Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=25e0b8adb35752d781eb5d677152ca29b3318012766c800a6e41c2bfe78fafe6&itok=goj-kO6R)
Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice were injected with GL261-luc2 cells, a cell line sharing characteristics of human glioblastoma multiforme (GBM). The mice were imaged using magnetic resonance (MR) at five separate time points to characterize growth and development of the tumor. After 25 days, the final tumor volumes of the mice varied from 12 mm3 to 62 mm3, even though mice were inoculated from the same tumor cell line under carefully controlled conditions. We generated hypotheses to explore large variances in final tumor size and tested them with our simple reaction-diffusion model in both a 3-dimensional (3D) finite difference method and a 2-dimensional (2D) level set method. The parameters obtained from a best-fit procedure, designed to yield simulated tumors as close as possible to the observed ones, vary by an order of magnitude between the three mice analyzed in detail. These differences may reflect morphological and biological variability in tumor growth, as well as errors in the mathematical model, perhaps from an oversimplification of the tumor dynamics or nonidentifiability of parameters. Our results generate parameters that match other experimental in vitro and in vivo measurements. Additionally, we calculate wave speed, which matches with other rat and human measurements.
![148396-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-07/148396-Thumbnail%20Image.png?versionId=iRYQkrl7IWsmbf4MHyi_kg_Uu69JmA9J&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T190511Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=37e7b345f69016f724bb27d88aac3c801b20d86d307bb95e0f1e6a58ac60ff4d&itok=UMffMZb6)
Over time, tumor treatment resistance inadvertently develops when androgen de-privation therapy (ADT) is applied to metastasized prostate cancer (PCa). To combat tumor resistance, while reducing the harsh side effects of hormone therapy, the clinician may opt to cyclically alternates the patient’s treatment on and off. This method,known as intermittent ADT, is an alternative to continuous ADT that improves the patient’s quality of life while testosterone levels recover between cycles. In this paper,we explore the response of intermittent ADT to metastasized prostate cancer by employing a previously clinical data validated mathematical model to new clinical data from patients undergoing Abiraterone therapy. This cell quota model, a system of ordinary differential equations constructed using Droop’s nutrient limiting theory, assumes the tumor comprises of castration-sensitive (CS) and castration-resistant (CR)cancer sub-populations. The two sub-populations rely on varying levels of intracellular androgen for growth, death and transformation. Due to the complexity of the model,we carry out sensitivity analyses to study the effect of certain parameters on their outputs, and to increase the identifiability of each patient’s unique parameter set. The model’s forecasting results show consistent accuracy for patients with sufficient data,which means the model could give useful information in practice, especially to decide whether an additional round of treatment would be effective.
![130350-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130350-Thumbnail%20Image.png?versionId=w3dG6iWiJ7Jasvugcwrgw.8FSiNaZnFt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240605/us-west-2/s3/aws4_request&X-Amz-Date=20240605T170724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5f6a567148781deda2b2127cea49a69bf03bb9d1363d553f03ee72983f413f09&itok=D7ID6Po8)
The membrane proximal region (MPR, residues 649–683) and transmembrane domain (TMD, residues 684–705) of the gp41 subunit of HIV-1’s envelope protein are highly conserved and are important in viral mucosal transmission, virus attachment and membrane fusion with target cells. Several structures of the trimeric membrane proximal external region (residues 662–683) of MPR have been reported at the atomic level; however, the atomic structure of the TMD still remains unknown. To elucidate the structure of both MPR and TMD, we expressed the region spanning both domains, MPR-TM (residues 649–705), in Escherichia coli as a fusion protein with maltose binding protein (MBP). MPR-TM was initially fused to the C-terminus of MBP via a 42 aa-long linker containing a TEV protease recognition site (MBP-linker-MPR-TM).
Biophysical characterization indicated that the purified MBP-linker-MPR-TM protein was a monodisperse and stable candidate for crystallization. However, crystals of the MBP-linker-MPR-TM protein could not be obtained in extensive crystallization screens. It is possible that the 42 residue-long linker between MBP and MPR-TM was interfering with crystal formation. To test this hypothesis, the 42 residue-long linker was replaced with three alanine residues. The fusion protein, MBP-AAA-MPR-TM, was similarly purified and characterized. Significantly, both the MBP-linker-MPR-TM and MBP-AAA-MPR-TM proteins strongly interacted with broadly neutralizing monoclonal antibodies 2F5 and 4E10. With epitopes accessible to the broadly neutralizing antibodies, these MBP/MPR-TM recombinant proteins may be in immunologically relevant conformations that mimic a pre-hairpin intermediate of gp41.
![133015-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/133015-Thumbnail%20Image.png?versionId=l7Ze8stpTOhUOtoQ1PMh1wC4l44FR5Pc&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T143615Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=14a18b372d6d6f0d9c61f9dd29ead93c025a76a69e0cc484ce827559759ec337&itok=5kbSLzbY)